AP

ARS Pharmaceuticals, Inc.

SPRY·NASDAQ

$9.07

+1.9%
HealthcareBiotechnology

ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.

At a Glance

Live Snapshot
Market Cap$900.68M
EPS-1.7400
P/E Ratio-5.21
Earnings Date08/12/2026

spry

Total Current Liabilities

Last Annual Value

39.15M

3-Year CAGR

93%

5-Year CAGR

37%

10-Year CAGR

23%

AP

ARS Pharmaceuticals, Inc. Competitors Analysis of Total Current Liabilities

SPRY · NASDAQ
CompanyTotal Current Liabilities
CAGR 3Y
CAGR 5Y
CAGR 10Y
39.15M
153.9%36.7%N/A 
6.01M
-35.6%-11.8%-5.5%
SVRA logo
Savara Inc.
NASDAQ:SVRA
20.40M
24.4%6.8%19.4%
116.97M
49.1%39.1%35.9%
11.34M
68.8%-25.8%N/A
21.19M
4.6%76.0%N/A
PROK logo
ProKidney Corp.
NASDAQ:PROK
30.74M
7.1%20.1%N/A
18.09M
5.7%38.0%N/A
RZLT logo
Rezolute, Inc.
NASDAQ:RZLT
11.91M
31.8%43.3%21.3%
AP

ARS Pharmaceuticals, Inc. Fair Value Envelope

SPRY · NASDAQ

Our analysis suggests that SPRY has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $9.07, this represents a potential HIDDEN relative to our calculated worth for ARS Pharmaceuticals, Inc..

Intrinsic Value
Current Price: $9.07